The University of Osaka · Medicine
Professor Yasufumi Gon's research lab focuses on the intersection of cerebrovascular disease and cancer, particularly investigating the pathophysiological links between active cancer and cryptogenic stroke. The lab explores biomarkers such as D-dimer and multi-vascular lesions to improve the detection of occult cancer in stroke patients. A key research direction involves identifying prognostic factors and long-term outcomes in patients with ischemic stroke and active or metastatic cancer, with an emphasis on hypercoagulable states and systemic inflammation. The lab also leverages electronic medical records for clinical research, emphasizing outcome validation and diagnostic accuracy.
Figures are computed from collected data and may differ slightly.
In cryptogenic stroke, patients with active cancer has a unique pathology characterized by high plasma D-dimer levels and multiple vascular lesions. The hypercoagulable state and malnutrition due to cancer and its treatments potentially influence the development of cryptogenic stroke in cancer patients.
High plasma D-dimer levels and lesions in multiple vascular regions can be used to predict occult cancer in patients with cryptogenic stroke.
Cancer survivors have a higher risk of fatal heart disease than the general population.
Combining the diagnostic code and clinical examination improved the proportion of the presence of disease in the diagnostic code and achieved appropriate accuracy for research. Clinical research using EMRs require outcome validation prior to conducting a study.
Background Limited data exist on the prognostic factors for patients with ischemic stroke and active cancer. Methods and Results We conducted a prospective, multicenter, observational study in Japan, including patients with acute ischemic stroke and active cancer, to investigate the prognostic factors. We followed up the patients for 1 year after stroke onset. The patients were divided into 2 groups according to cryptogenic stroke and known causes (small-vessel occlusion, large-artery atheroscle
The results suggest that cancer, especially distant metastatic cancer, is an independent predictor of poorer outcomes following ICH.
The risk for ATE varies according to sex, age, and cancer progression and type. Antithrombotic therapy after ATE is associated with improved survival among patients with cancer.
The proportion of non-cancer-related deaths among cancer patients has increased over time, emphasizing the need to manage cancer and its comorbidities carefully.
Open papers in the app to read, cite, and organize with AI.
